Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-2536. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 15/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | TAF1 | P21675 | 5/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-2536 SCHEMBL29395966 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL614114 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL372489 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL29644993 | 0.99 | BRD4 (0.99) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL13227794 | 0.96 | BRD4 (0.92) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL24851804 | 0.96 | PLK1 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL4515444 | 0.95 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972068 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972069 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL376236 | 0.94 | PLK1 (0.89) | BRD4PLK1PLK3ALKTAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2015117055-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | PPP5C, PPP4C, DUSP26 | PLK1 314/4885BRD4 1691/4885PLK3 1911/4885 |
| US-20160347750-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | PLK1 2859/4885BRD4 2/4885PLK3 2255/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | PLK1 306/4885BRD4 1/4885PLK3 1580/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PLK1 121/4885BRD4 205/4885PLK3 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.